Impact portfolio.
Dementia ideas ranked with the same disclosed-dimension engine OnCo used for capital requests — retargeted to Need × Tractability. Missing DALYs stay Not scored. Not medical advice; not a donation ranking.
Burden context
Cite the burden. Score only what the atlas has.
Ideas below come from dementia-atlas seed. Walk bottleneck → idea → diagnosis → trial from each card.
Global dementia DALYs
Use GBD/IHME results for country- and age-specific disability-adjusted life years. This atlas does not hardcode a single DALY total as a product fact — the Burden dimension on ranked ideas stays Not scored until a cited figure is attached.
GBD Results Tool (IHME) — dementia DALYsEconomic burden projections
Peer-reviewed work projects large and shifting ADRD economic burden through 2050. Use for context when sizing portfolios — not as an effectiveness score for a medicine or idea.
Nandi et al., eClinicalMedicine 2022 (ADRD burden projections)
Ranked ideas
Need × tractability on this atlas.
Composite is the geometric mean of Need and Tractability when both axes have at least one scored dimension. Unscored dimensions (including DALYs/$) are dropped, not guessed.
Judge dementia treatments by whether households cope better, not only by a clinic memory score.
Need100Tractability50Composite71How this was scored (3 of 7 dimensions)
- Bottleneck severityNeed · weight 0.45100/100Named by 1 bottleneck; worst severity criticalFrom Unpaid care as the hidden delivery system (severity critical)
- Approved optionsNeed · weight 0.35not scoredNot scoredThe idea names no dementia diagnosis, so approved-option counts cannot be attached
- Burden (DALYs)Need · weight 0.2not scoredNot scoredNo cited DALY figure on this idea yet — see impact methodology and GBD/IHMEFrom Make carer outcomes a primary trial endpoint, GBD Results Tool (IHME) (burden source family)
- WhitespaceTractability · weight 0.3not scoredNot scoredThe idea names neither a technology nor a diagnosis to match companies and trials against
- Capital to proofTractability · weight 0.25100/100Medium: one to fifty million dollarsFrom Make carer outcomes a primary trial endpoint (cost field)
- Evidence readinessTractability · weight 0.250/100speculativeFrom Make carer outcomes a primary trial endpoint (maturity field)
- DALYs per dollarTractability · weight 0.2not scoredNot scoredRequires cited ideal benefit × P(success) × attribution ÷ cost — see docs/impact-roi-methodology.md
Test amyloid antibodies in the mixed, comorbid people clinics actually see, instead of only in tidy trial cohorts.
Need44Tractability0Composite0How this was scored (5 of 7 dimensions)
- Bottleneck severityNeed · weight 0.450/100Named by 1 bottleneck; worst severity majorFrom Trial populations that skip mixed disease (severity major)
- Approved optionsNeed · weight 0.35100/1000 approved products in the corpus for Mixed dementiaFewest of 2 diagnoses namedFrom Mixed dementia (counted from dementia drug records with an approval)
- Burden (DALYs)Need · weight 0.2not scoredNot scoredNo cited DALY figure on this idea yet — see impact methodology and GBD/IHMEFrom Antibody trials that enrol mixed and comorbid disease, GBD Results Tool (IHME) (burden source family)
- WhitespaceTractability · weight 0.30/1000 companies and 4 trials on the same 2 diagnosisesFrom Alzheimer’s disease (matched diagnosis), Mixed dementia (matched diagnosis), CLARITY AD (trial on it), ENGAGE (trial on it), EXPEDITION 3 (trial on it), TRAILBLAZER-ALZ 2 (trial on it)
- Capital to proofTractability · weight 0.250/100Large: over fifty million dollarsFrom Antibody trials that enrol mixed and comorbid disease (cost field)
- Evidence readinessTractability · weight 0.250/100speculativeFrom Antibody trials that enrol mixed and comorbid disease (maturity field)
- DALYs per dollarTractability · weight 0.2not scoredNot scoredRequires cited ideal benefit × P(success) × attribution ÷ cost — see docs/impact-roi-methodology.md
Use a blood test to decide who still needs a scan or spinal-fluid test, instead of sending everyone to PET.
Need0Tractability100Composite0Attacks Late and uneven diagnosisHow this was scored (5 of 7 dimensions)
- Bottleneck severityNeed · weight 0.450/100Named by 1 bottleneck; worst severity majorFrom Late and uneven diagnosis (severity major)
- Approved optionsNeed · weight 0.350/1002 approved products in the corpus for Mild cognitive impairmentFewest of 2 diagnoses namedFrom Mild cognitive impairment (counted from dementia drug records with an approval)
- Burden (DALYs)Need · weight 0.2not scoredNot scoredNo cited DALY figure on this idea yet — see impact methodology and GBD/IHMEFrom Blood test before PET or lumbar puncture, GBD Results Tool (IHME) (burden source family)
- WhitespaceTractability · weight 0.3100/1000 companies and 0 trials on the same 1 technology and 2 diagnosisesFrom Blood Alzheimer biomarkers (matched technology), Alzheimer’s disease (matched diagnosis), Mild cognitive impairment (matched diagnosis)
- Capital to proofTractability · weight 0.25100/100Medium: one to fifty million dollarsFrom Blood test before PET or lumbar puncture (cost field)
- Evidence readinessTractability · weight 0.25100/100early clinicalFrom Blood test before PET or lumbar puncture (maturity field)
- DALYs per dollarTractability · weight 0.2not scoredNot scoredRequires cited ideal benefit × P(success) × attribution ÷ cost — see docs/impact-roi-methodology.md
Methodology
Disclosed dimensions + expected return.
Ranking engine: same min-max normalisation and weighted axes as OnCo's startup requests, retargeted in src/lib/impact-score.ts. Philanthropic expected return (ideal DALYs × P(success) × attribution ÷ cost) is documented in docs/impact-roi-methodology.md and will populate the DALYs/$ dimension only when every factor is cited.
- Never invent DALYs, costs, or probabilities — label gaps Not scored.
- Every numeric claim needs a primary URL on the record.
- Licence ≠ funding; see approvals separately.
- No DIY experimental-treatment ROI or home protocols.
Related map: bottlenecks · ideas · Who · trials.